Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer

2.1 Pembrolizumab (Keytruda, MSD) has a marketing authorisation 'in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence'.

2.2 The dosage schedule is available in the summary of product characteristics for pembrolizumab.

2.3 The list price is £2,630 per 100 mg solution for infusion vial (excluding VAT; BNF online accessed September 2022).

2.4 The company has a commercial arrangement. This makes pembrolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.